Table 3.
Multivariate logistic regression analysis of clinical biological indicators and the disease activity of SLE.
| Parameters | Model I | Model II | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Age | 1.029 | 0.977–1.085 | 0.278 | 0.990 | 0.916–1.072 | 0.811 |
| Sex | 0.862 | 0.053–14.090 | 0.917 | 0.646 | 0.037–11.420 | 0.766 |
| HCQ blood concentration | 0.995 | 0.990–0.999 | 0.018* | 0.994 | 0.990–0.999 | 0.013* |
| Duration of HCQ treatment | 0.990 | 0.962–1.019 | 0.491 | 0.981 | 0.951–1.013 | 0.237 |
| Cumulative dose of HCQ | 1.001 | 0.997–1.004 | 0.748 | 1.000 | 0.995–1.005 | 0.972 |
| Daily dose of HCQ | 1.003 | 0.989–1.017 | 0.675 | 1.006 | 0.990–1.022 | 0.456 |
| Body mass dependent dose | 1.149 | 0.630–2.096 | 0.651 | 1.009 | 0.498–2.045 | 0.979 |
| Duration of SLE | – | – | – | 1.013 | 0.969–1.059 | 0.568 |
| GCs dosage | – | – | – | 0.995 | 0.851–1.164 | 0.951 |
| ISA | – | – | – | 0.486 | 0.112–2.099 | 0.333 |
| eGFR | – | – | – | 0.972 | 0.930–1.015 | 0.195 |
OR odds ratio, CI confidence interval, HCQ hydroxychloroquine, SLE systemic lupus erythematosus, GCs glucocorticoids, ISA immunosuppressant.
Model I adjusted for: Age, Sex, and parameters of HCQ (HCQ blood concentration, Duration of HCQ treatment, Cumulative dose of HCQ, Daily dose of HCQ, Body mass dependent dose of HCQ). Model II adjusted for: Age, Sex, parameters of HCQ (HCQ blood concentration, Duration of HCQ treatment, Cumulative dose of HCQ, Daily dose of HCQ, Body mass dependent dose of HCQ), Duration of SLE, GCs dosage, ISA, and eGFR.
*P < 0.05 was considered statistically significant.